en sv

A letter to NextCell’s Investors

Cellaviva Sverige - July 19, 2019 - 0 comments

NextCell Pharma AB (“NextCell”) has published a letter to the investors with summer greetings from CEO Mathias Svahn. The attached letter is in Swedish and can also be found on www.nextcellpharma.com.

It has been two years since NextCell was listed on the Spotlight Stock Market. We have worked fast and hard with full focus on developing stem cell-based treatments for complex and currently incurable diseases.

Over the past year, we have managed to significantly increase Cellaviva’s sales and accelerate the clinical trial program with ProTrans for the treatment of diabetes. We now run two phase IIa studies.

NextCell is an innovative and entrepreneurial company with scientific weight. We are confident in our expertise and dare to think outside the box of a classic life science company. We will offer a continued exciting and eventful journey.

I wish you a wonderful summer!

Stay up to date with the latest development in NextCell Pharma

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Sofia Fredrikson, CFO

Phone: 08-735 5595

E-mail: info@nextcellpharma.com